NPAT fell 75% to $15.4m while net debt pushed leverage to 6.9x EBITDA

What changed

Revenue rose 6.9% to $247.2m and Underlying EBITDA (the company's preferred measure) was reported up 5% to $80.0m. Realised development and resale gains grew 5% to $59.4m. Below that line the picture inverts: statutory NPAT fell 74.7% to $15.4m from $61.1m, operating cash flow fell 33.5% to $70.2m, and drawn debt and bonds net of cash rose to $550.3m (FY22: ~$370.4m). Total assets grew 15.8% to $2.5b, consistent with continued build-out rather than deleveraging. A final dividend of 1.3 cps was declared, alongside a new policy of 30–50% of Underlying EBIT.

What matters

• Leverage step-change. Net debt of $550.3m against Underlying EBITDA of $80.0m implies roughly 6.9x, up from about 4.4x a year earlier. Capex of $164.0m against operating cash flow of $70.2m drove pre-lease free cash flow to roughly -$93.8m (FY22: -$59.6m), so the debt build is structural to the current development spend, not a one-off funding event.
• Earnings quality divergence. Headline Underlying EBITDA growth of 5% sits against a 4.9% decline in the statutory EBITDA figure in the accounts and a 75% fall in NPAT. FY23 PBT was not disclosed in the supplied material, so the NPAT/PBT bridge and any tax effect cannot be quantified — but the release does not point to a discrete discontinued operation or disposal loss to explain the gap.
• Cash conversion deteriorated materially. OCF/EBITDA fell to 87.8% from 125.4%, a 37.6pp compression in a year when reported revenue and Underlying EBITDA both moved up.

Expectations

No quantified revenue, EBITDA or forward-sales target was supplied, and no FY24 guidance was identified. HY23 represented 70.1% of FY23 revenue and delivered a $24.1m NPAT loss, so the implied second half — roughly $73.9m of revenue and about $39.6m of NPAT — did the heavy lifting on full-year profitability. That shape suggests revaluation and resale timing, rather than steady operating flow, is carrying the annual result, and the release does not provide a forward order book to anchor FY24 expectations.

Quality of result

The durable component is modest: realised development and resale gains of $59.4m grew 5%, and Underlying EBITDA grew at a similar pace. Against that, the release relies on a non-GAAP earnings measure without a full reconciliation to statutory NPAT in the supplied excerpt, statutory earnings fell sharply, and operating cash flow fell 33.5% while capex stayed at $164.0m. The second-half NPAT swing of roughly $39.6m after a first-half loss also leans on period-end valuation and settlement timing typical of retirement-village accounting. On balance, the headline "5% EBITDA growth" overstates how much of the result is recurring operating earnings.

Unresolved

• FY23 PBT, tax expense, and the bridge from Underlying EBITDA to statutory NPAT are not in the supplied excerpts, so the driver of the 75% NPAT decline cannot be isolated between fair-value movements, interest, depreciation/amortisation and tax.
• FY23 closing cash, gross borrowings, total equity and trade debtors were not disclosed in the supplied material, leaving the exact net-debt composition, covenant headroom beyond the stated "undrawn" comment, and working-capital trend unverified.
• The new dividend policy references 30–50% of Underlying EBIT, but Underlying EBIT itself was not supplied, so the implied payout range and its coverage by free cash flow cannot be tested.
• No FY23 segment split was provided; the FY22 pattern (Care Operations low/negative margin, Village Operations carrying profit) cannot be confirmed as intact.

This briefing cannot assess whether the reported Underlying EBITDA growth reconciles cleanly to statutory earnings, because the supplied excerpts do not include the full non-GAAP reconciliation or FY23 PBT and tax lines.

Key metrics

Segment breakdown

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.